Efficacy of a reduced dose of darunavir/ritonavir in a cohort of antiretroviral-naive and -experienced HIV-infected patients: a medium-term follow-up

J Antimicrob Chemother. 2015 Feb;70(2):627-30. doi: 10.1093/jac/dku390. Epub 2014 Oct 8.

Authors

Massimiliano Lanzafame¹, Emanuela Lattuada², Fabio Rigo², Anna Ferrari², Andrew Hill³, Sandro Vento⁴

Affiliations

¹ Infectious Diseases Unit, G.B. Rossi Hospital, Verona, Italy lanzafame.massimiliano@gmail.com.
² Infectious Diseases Unit, G.B. Rossi Hospital, Verona, Italy.
³ Department of Pharmacology and Therapeutics, Liverpool University, Liverpool, UK.
⁴ Department of Internal Medicine, Faculty of Medicine, University of Botswana, Gaborone, Botswana.

PMID: 25298517
DOI: 10.1093/jac/dku390

No abstract available

Keywords: antiviral; dose optimization; pharmacokinetics.

Publication types

Letter
Comment

MeSH terms

Anti-HIV Agents / administration & dosage*
Anti-HIV Agents / pharmacokinetics*
Female
HIV Infections / drug therapy*
Humans
Male
Ritonavir / administration & dosage*
Ritonavir / pharmacokinetics*
Sulfonamides / administration & dosage*
Sulfonamides / pharmacokinetics*

Substances

Anti-HIV Agents
Sulfonamides
Ritonavir